Biogen (BIIB) Asset Writedowns and Impairment (2009 - 2026)

Biogen's Asset Writedowns and Impairment history runs 11 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 34.25% year-over-year to $4.8 million; the TTM figure through Jun 2026 stood at $57.7 million (down 10.12% YoY), while the FY2025 annual figure was $52.9 million, down 48.09% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $4.8 million, down from $52.9 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $275.0 million in Q1 2022, with the low at $3.5 million in Q2 2025.
• The 5-year median for Asset Writedowns and Impairment is $30.4 million (2024), against an average of $96.3 million.
• The sharpest annual moves came in 2022 and 2023: Asset Writedowns and Impairment jumped 1733.33% in 2022, then plunged 93.67% in 2023.
• Biogen's Asset Writedowns and Impairment stood at $275.0 million in 2022, then plunged by 77.35% to $62.3 million in 2023, then sank by 46.71% to $33.2 million in 2024, then soared by 59.34% to $52.9 million in 2025, then slumped by 90.93% to $4.8 million in 2026.
• Business Quant data shows BIIB's Asset Writedowns and Impairment at $4.8 million in Q1 2026, $52.9 million in Q4 2025, and $3.5 million in Q2 2025.